Epigenomics Future Growth
Future criteria checks 2/6
Epigenomics is forecast to grow earnings and revenue by 95.7% and 36.9% per annum respectively while EPS is expected to grow by 103.2% per annum.
Key information
95.7%
Earnings growth rate
103.2%
EPS growth rate
| Biotechs earnings growth | 19.0% |
| Revenue growth rate | 36.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Aug 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -1 | 0 | 0 | 2 |
| 12/31/2024 | 0 | -1 | 1 | 1 | 2 |
| 12/31/2023 | 1 | -7 | -9 | -9 | 2 |
| 6/30/2023 | 0 | -16 | -14 | -13 | N/A |
| 3/31/2023 | 1 | -15 | -13 | -12 | N/A |
| 12/31/2022 | 0 | -12 | -13 | -12 | N/A |
| 9/30/2022 | 1 | -7 | -10 | -9 | N/A |
| 6/30/2022 | 6 | -3 | -6 | -6 | N/A |
| 3/31/2022 | 6 | -4 | -5 | -5 | N/A |
| 12/31/2021 | 6 | -2 | -4 | -4 | N/A |
| 9/30/2021 | 6 | -3 | -6 | -6 | N/A |
| 6/30/2021 | 1 | -9 | -8 | -8 | N/A |
| 3/31/2021 | 1 | -10 | -9 | -9 | N/A |
| 12/31/2020 | 1 | -12 | -10 | -10 | N/A |
| 9/30/2020 | 1 | -16 | -10 | -10 | N/A |
| 6/30/2020 | 1 | -16 | -11 | -11 | N/A |
| 3/31/2020 | 1 | -17 | -13 | -12 | N/A |
| 12/31/2019 | 1 | -17 | -14 | -14 | N/A |
| 9/30/2019 | 1 | -14 | -15 | -14 | N/A |
| 6/30/2019 | 1 | -14 | -14 | -14 | N/A |
| 3/31/2019 | 2 | -12 | -12 | -12 | N/A |
| 12/31/2018 | 2 | -13 | -10 | -10 | N/A |
| 9/30/2018 | 2 | -11 | -10 | -10 | N/A |
| 6/30/2018 | 2 | -10 | -10 | -9 | N/A |
| 3/31/2018 | 2 | -11 | -11 | -11 | N/A |
| 12/31/2017 | 2 | -10 | -10 | -10 | N/A |
| 9/30/2017 | 3 | -9 | -13 | -12 | N/A |
| 6/30/2017 | 3 | -10 | -15 | -14 | N/A |
| 3/31/2017 | 4 | -9 | N/A | -12 | N/A |
| 12/31/2016 | 4 | -11 | N/A | -13 | N/A |
| 9/30/2016 | 3 | -11 | N/A | -10 | N/A |
| 6/30/2016 | 3 | -11 | N/A | -8 | N/A |
| 3/31/2016 | 2 | -10 | N/A | -8 | N/A |
| 12/31/2015 | 2 | -9 | N/A | -8 | N/A |
| 9/30/2015 | 2 | -11 | N/A | -9 | N/A |
| 6/30/2015 | 2 | -10 | N/A | -9 | N/A |
| 3/31/2015 | 1 | -10 | N/A | -8 | N/A |
| 12/31/2014 | 2 | -9 | N/A | -7 | N/A |
| 9/30/2014 | 2 | -8 | N/A | -7 | N/A |
| 6/30/2014 | 2 | -8 | N/A | -6 | N/A |
| 3/31/2014 | 2 | -8 | N/A | -6 | N/A |
| 12/31/2013 | 2 | -7 | N/A | -7 | N/A |
| 9/30/2013 | 1 | -8 | N/A | -9 | N/A |
| 6/30/2013 | 1 | -10 | N/A | -10 | N/A |
| 3/31/2013 | 1 | -12 | N/A | -10 | N/A |
| 12/31/2012 | 1 | -12 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0QXH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0QXH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0QXH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0QXH's revenue (36.9% per year) is forecast to grow faster than the UK market (4% per year).
High Growth Revenue: 0QXH's revenue (36.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0QXH's Return on Equity is forecast to be high in 3 years time